Navigation Links
CNIO researchers discover a new therapy that prevents lung cancer growth in mice
Date:8/13/2012

Lung cancer is one of the most aggressive types of cancer and the most common cause of death from this disease worldwide. Despite the progress in the molecular biology of lung cancer achieved in recent years, the mechanisms used by tumor cells to grow and spread throughout the body are not yet completely understood. This lack of information is responsible for the limited range of available therapeutic possibilities and their undesirable side effects.

The Tumour Suppression Group of the Spanish National Cancer Research Centre (CNIO), led by Manuel Serrano, has deciphered one of the molecular pathways behind lung cancer. Using this information, the authors have identified an experimental drug, which blocks lung cancer growth in mice. This work is published today in the scientific journal Cancer Cell.

Standing up to lung cancer

Notch was identified in 2004 as an important oncogene for the development of leukemias and, since then, intense efforts have been devoted to study the role of Notch in other cancers. At the end of the last decade it was found that Notch is also involved in the development of pancreatic and lung cancer.

In this study, Serrano's team has identified the molecular pathways by which Notch regulates cell proliferation in lung cancer. "We have found that this protein cooperates with the Ras oncogene, a key element in the formation of these tumors", states Serrano.

Researchers have also discovered the therapeutic effect of a specific experimental drug which blocks Notch efficiently, named GSIs (Gamma-Secretase Inhibitors). To this end, scientists used genetically modified mice previously developed by Mariano Barbacid, head of the Experimental Oncoloy Group at the CNIO, that faithfully recapitulate human lung cancer. "After 15 days of treatment, lung tumors failed to grow without treatment-related side effects", says Antonio Maraver, the first author of the study.

Co-clinical trials both in humans and mice

GSIs were developed over 15 years ago to treat Alzheimer's disease. Although now it is well established that GSIs are not useful to stop this neurodegenerative disease, the discovery that these drugs block Notch has stirred the interest in their possible application for cancer. The accumulated knowledge acquired over the years on the pharmacological properties of GSIs has permitted their immediate use in clinical trials for cancer.

Mouse therapeutic trials performed in parallel with humans clinical trials are called coclinical trials, and are at the cutting edge of biomedical research. These trials allow the transference of information from mice to humans in a very short period of time. A clear example is this research, which is being accompanied by a human clinical trial led by Manuel Hidalgo, director of the Clinical Research Program at the CNIO.

"The assays developed by Serrano led us to believe that blocking Notch could be beneficial for treating lung cancer. We have already treated a dozen patients with an agent directed at the blocking of this protein. We are expanding the study, but I can anticipate that the results are very promising", says Hidalgo.


'/>"/>
Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. BUSM researchers part of multi-center study on cardiac amyloidosis
2. BUSM/VA researchers uncover gender differences in the effects of long-term alcoholism
3. Excellence Initiative winner TU München invests in the future: Young researchers
4. Clemson researchers collect and reuse enzymes while maintaining bioactivity
5. Healthcare researchers recognized at SingHealth Duke-NUS Scientific Congress 2012
6. Northwestern researchers investigate treatment for tumor cells in spinal fluid
7. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
8. MDC researchers develop new approach to treat acute liver failure
9. Breast Cancer Charity Overstates Value of Mammograms: Researchers
10. Boston University researchers expand synthetic biologys toolkit
11. Global health researchers urge integrating de-worming into HIV care in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
Breaking Medicine Technology: